CaptureSelect™ FcXL Affinity Matrix has been specifically designed for the purification of recombinant human IgG, Fc fusion proteins, and plasma derived IgG. It recognizes the CH3 domain of all human IgG subclasses (IgG1, 2, 3, and 4).

Features of this affinity matrix include:

• Mild elution, making it suitable for Fc fusion proteins
• Human specific, no binding to bovine antibodies, for example
• Excellent scalability
• Non-animal-derived

CaptureSelect™ FcXL Affinity Matrix purifies IgGs and Fc fusion proteins directly from complex source materials in a single step with high purity and yield.

Free of animal components

CaptureSelect products contain affinity ligands based on recombinant single-domain antibody fragments (VHH) created by a proprietary technology. The VHH affinity ligand is a 12 to 15 kDa fragment comprising the three complementarity-determining regions (CDRs) that form the antigen-binding domain, efficiently produced in the yeast Saccharomyces cerevisiae by a production process free of any animal components (Animal Origin-Free).

Main Characteristics:

• Matrix: agarose-based, aldehyde-activated
• Average particle size: 65 ± 10 μm
• Ligand: CaptureSelect™ FcXL affinity ligand
• Ligand coupling method: aldehyde coupling via NH₂ residues of the ligand
• Binding capacity: 25–35 g IgG/L resin depending on flow rate, column height, and contact time
• Elution conditions: 20 mM citric acid or acetic acid, pH 3–4, or 20 mM sodium acetate, 1.0 M MgCl₂, 40% (v/v) propylene glycol, pH 5–6
• Flow characteristics: 50–200 cm/h (up to 2 bar)
• Formulation buffer: 20%(v/v) ethanol